These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17663306)

  • 21. Pharmacological management of a youth with ADHD and a seizure disorder.
    Gonzalez-Heydrich J; Weiss M; Connolly M; Wambera K; Jan JE; Plioplys S; Dunn DW; Kratochvil CJ
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1527-32. PubMed ID: 17135999
    [No Abstract]   [Full Text] [Related]  

  • 22. Attention-Deficit/Hyperactivity Disorder.
    Leung AK; Hon KL
    Adv Pediatr; 2016 Aug; 63(1):255-80. PubMed ID: 27426904
    [No Abstract]   [Full Text] [Related]  

  • 23. [Attention-deficit/hyperactivity disorder. Clinical and treatment aspects].
    Diaconu G; Grigore I; Burlea M
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(3):656-62. PubMed ID: 20191811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis and management of adult attention-deficit/hyperactivity disorder.
    Post RE; Kurlansik SL
    Am Fam Physician; 2012 May; 85(9):890-6. PubMed ID: 22612184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Attention deficit hyperactivity disorder: clinical heterogeneity and possibilities of therapy].
    Chutko LS; Surushkina SIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(8):75-80. PubMed ID: 19115509
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of stimulants and atomoxetine on cortisol levels in children with ADHD.
    Isaksson J; Hogmark Å; Nilsson KW; Lindblad F
    Psychiatry Res; 2013 Oct; 209(3):740-1. PubMed ID: 23850434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands.
    Hodgkins P; Sasané R; Meijer WM
    Clin Ther; 2011 Feb; 33(2):188-203. PubMed ID: 21497704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD.
    Faraone SV; Wigal SB; Hodgkins P
    J Atten Disord; 2007 Jul; 11(1):74-82. PubMed ID: 17606774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Righting a troubled course. Diagnosing and treating ADHD in adults.
    McDonnell MA; Dougherty M
    Adv Nurse Pract; 2005 Aug; 13(8):53-6. PubMed ID: 16117012
    [No Abstract]   [Full Text] [Related]  

  • 30. Primary care treatment of attention-deficit/hyperactivity disorder.
    Culpepper L
    J Clin Psychiatry; 2006; 67 Suppl 8():51-8. PubMed ID: 16961431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD).
    NIH Consens Statement; 1998 Nov 16-18; 16(2):1-37. PubMed ID: 10868163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.
    Brown RT; Amler RW; Freeman WS; Perrin JM; Stein MT; Feldman HM; Pierce K; Wolraich ML; ;
    Pediatrics; 2005 Jun; 115(6):e749-57. PubMed ID: 15930203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical practice. Attention deficit-hyperactivity disorder.
    Rappley MD
    N Engl J Med; 2005 Jan; 352(2):165-73. PubMed ID: 15647579
    [No Abstract]   [Full Text] [Related]  

  • 35. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of action of agents used in attention-deficit/hyperactivity disorder.
    Wilens TE
    J Clin Psychiatry; 2006; 67 Suppl 8():32-8. PubMed ID: 16961428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines.
    Ramos-Quiroga JA; Montoya A; Kutzelnigg A; Deberdt W; Sobanski E
    Curr Med Res Opin; 2013 Sep; 29(9):1093-104. PubMed ID: 23742051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Attention-deficit/hyperactivity disorder (ADHS) in adulthood].
    Kordon A; Kahl KG
    Psychother Psychosom Med Psychol; 2004; 54(3-4):124-36. PubMed ID: 15037976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.